Hepatitis C Antivirals Prior Authorization Guideline
Customize your policy alerts
Sign up for all careoregon policy alerts
Know when careoregon releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization guideline for coverage and approval of hepatitis C direct-acting antiviral (DAA) therapies (e.g., sofosbuvir/velpatasvir, Mavyret, Vosevi, Zepatier, Harvoni) for members needing treatment; intended for providers submitting requests to CareOregon.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Initial and retreatment coverage criteria
Covered when ALL of the following are met
Genotype testing in the past 3 years is required if the patient has decompensated cirrhosis, any prior treatment experience with a DAA regimen, or if prescribed a regimen which is not pan-genotypic.
Baseline NS5A resistance testing required for the specified regimens.
Refer to regimen tables for durations and special pediatric guidance.
Regimen tables summary
Regimen-specific approvals and durations (summary of background table guidance)
See background tables for cirrhosis-specific or genotype-specific exceptions (e.g., Sof/Vel + RBV for GT3 with decompensated cirrhosis).
Specific combinations and durations vary by genotype and prior regimen; consult the full regimen table.
Follow FDA pediatric approvals and consider hepatology consultation for treatment-experienced children.
Some specific regimens or regimen combinations are identified in the guideline as ineligible in certain situations. The source table lists a set of "ineligible" entries and treatment sequencing choices for prior DAA failures (for example, Vosevi, Mavyret ± Sovaldi ± ribavirin combinations and extended durations for multiple DAA failures), and notes that some combinations are not appropriate depending on prior regimen failure and cirrhosis status. Providers should consult the regimen tables in the background for the exact ineligible combinations and the recommended alternative retreatment regimens and durations.
The policy identifies criteria under which ribavirin is considered ineligible due to intolerance or laboratory thresholds. These include neutrophils < 750 mm3, hemoglobin < 10 g/dl, and platelets < 50,000 cells/mm3, as well as clinical factors such as autoimmune hepatitis or other autoimmune conditions and hypersensitivity or allergy to ribavirin. If any of these conditions apply, ribavirin-containing regimens should be considered not appropriate for the member.
Coding and Lab Thresholds
Prior Authorization, Documentation, and Provider Requirements
Prior authorization required; approve per regimen table
Prior authorization is required for hepatitis C direct-acting antivirals; approve for the appropriate duration listed in the regimen tables when all coverage criteria are met (e.g., requested drug is FDA‑approved, request is for HCV treatment, required clinical records provided, and prescribed regimen aligns with genotype/age/treatment/cirrhosis status).
- Approve for the duration specified in the regimen tables (see Background/Regimen tables).
- PA applies to listed products such as sofosbuvir/velpatasvir, Mavyret, Vosevi, Zepatier, Harvoni as referenced in the criteria.
Follow regimen selection and retreatment sequencing in guideline tables
Select regimens and sequence retreatment according to the guideline tables: preferred options include Vosevi or Mavyret-based approaches for many prior sofosbuvir-based failures and specific extended/combination regimens for multiple DAA failures. Choose regimen and duration based on genotype, cirrhosis status, pediatric age limits, and prior treatment history.
- For prior sofosbuvir-based failures: Vosevi for 12 weeks or Mavyret for extended duration (e.g., 16 weeks) as indicated by genotype and cirrhosis.
- For multiple DAA treatment failures: consider Vosevi, Mavyret + Sovaldi + RBV (16–24 weeks), or Vosevi for extended durations (up to 24 weeks) with RBV if cirrhosis.
- For treatment‑naïve/non‑cirrhotic: Mavyret 8 weeks or sofosbuvir/velpatasvir 12 weeks per table and age approvals.
Provide medical records: genotype testing, prior treatment history, and regimen
Submit medical records (e.g., chart notes) that document genotype testing when required, history of prior HCV treatment and outcome, and the requested regimen to support prior authorization.
- Genotype testing in the past 3 years is required if the patient has decompensated cirrhosis, any prior DAA treatment experience, or if a non‑pan‑genotypic regimen is prescribed.
- Include documentation of previous HCV treatment and treatment outcome (e.g., SVR status).
Risk of denial if genotype testing within 3 years is not provided when required
Requests missing documentation of genotype testing within the past 3 years when required (decompensated cirrhosis, prior DAA treatment experience, or prescription of a non‑pan‑genotypic regimen) may be denied.
- Genotype testing within 3 years is required for patients with decompensated cirrhosis, any prior DAA experience, or when prescribing a regimen that is not pan‑genotypic.
Baseline NS5A resistance testing required for specific regimen/genotype combinations
A baseline NS5A resistance test showing no resistant variant must be provided for requests of Zepatier for genotype 1a, Harvoni for genotype 1a treatment‑experienced infection, or sofosbuvir/velpatasvir for genotype 3 in cirrhosis or treatment‑experienced infection; absence of this result may result in denial.
- For Zepatier (elbasvir/grazoprevir) for GT1a — require baseline NS5A resistance test without resistant variant.
- For Harvoni (ledipasvir/sofosbuvir) for GT1a treatment‑experienced infection — require baseline NS5A resistance test without resistant variant.
- For sofosbuvir/velpatasvir (Epclusa) for GT3 in cirrhosis or treatment‑experienced infection — require baseline NS5A resistance test without resistant variant.
Background and Scope
The guideline summarizes approved direct-acting antiviral (DAA) regimens across genotypes and treatment histories, with regimen selection based on genotype, cirrhosis status, age, and prior treatment. For treatment-naïve adults, recommended options include Mavyret for 8 weeks or sofosbuvir/velpatasvir for 12 weeks depending on clinical factors. For treatment-experienced or prior sofosbuvir-based regimen failures, recommended retreatment options include Vosevi for 12 weeks or Mavyret for extended durations (e.g., 16 weeks), with additional combinations (for example, Mavyret + Sovaldi ± ribavirin) and longer courses for multiple DAA failures or for patients with cirrhosis. Pediatric approvals for ages 3–12 and adolescents are referenced and should follow FDA guidance and specialist consultation when treating children. The guideline also highlights special considerations such as required baseline NS5A resistance testing for certain regimen/genotype combinations and the ribavirin ineligibility criteria noted above.
Definitions and Patient Status
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.